Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

Jounce seeking tumor-agnostic approach for ICOS agonist

Chris Lieu, Staff Writer
March 9, 2019 12:15 AM UTC

Jounce said the ICOS hi CD4 T cells biomarker could allow the company to take a tumor-agnostic approach for its ICOS agonist vopratelimab (JTX-2011) to select patient populations more likely to respond to the therapy. Jounce Therapeutics Inc. (NASDAQ:JNCE) announced the news in its 4Q18 financial results Wednesday, then gained $1.06 (24%) to $5.45 on Thursday.

At the J.P. Morgan Healthcare Conference in January, President and CEO Richard Murray said that responses to vopratelimab were associated with emergence of the ICOS hi CD4 T cells biomarker...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Jounce Therapeutics Inc.